Effect of verapamil on retrograde atrioventricular nodal conduction in the human heart

Effects of cardioactive medications on retrograde conduction: Continuing relevance for current devices

INTRODUCTION

Retroconduction (ventriculo-atrial conduction) remains a problem for patients with implanted cardiac rhythm devices. Pacemaker algorithms can detect and terminate endless loop tachycardia (ELT), but actual prevention of ELT may require anti-arrhythmic drugs (AADs). Similarly, AADs can affect ICD rhythm discrimination algorithms that depend on atrio-ventricular ratios. There is concern whether these drugs remain effective during stress situations.

METHODS

Electrophysiologic studies that included retroconduction testing using slow ramp pacing were done in 1332 patients. The presence or absence of retroconduction at baseline and with drug was recorded, as was the rate at block. As a stress surrogate, isoproterenol was used to test retroconduction and reversal of drug-induced block.

RESULTS

Procainamide, mexiletine, phenytoin, disopyramide, quinidine, beta-blockers, encainide, and amiodarone caused complete retrograde block or decreased the rate at which block occurred (mean 76% of patients, p < 0.008), whereas digoxin, lidocaine, diltiazem, and verapamil did not. Isoproterenol (in the absence of AADs) increased the rate at block in 82% of 404 patients with retroconduction at baseline (p < 0.005). Of 319 patients without retroconduction at baseline, 134 (42%) developed retroconduction after isoproterenol. Isoproterenol reversed retrograde block in 39% of patients with block on an AAD. Amiodarone, digoxin, and the combination of digoxin plus a beta-blocker were most effective at resisting this reversal of ventriculo-atrial block (80%, 68%, and 75% respectively).

CONCLUSION

Most of the AADs reviewed increase the cycle length at block or abolish retroconduction, while isoproterenol has the opposite effect. Anti-arrhythmic medications, particularly amiodarone, digoxin, and the combination of digoxin plus a beta-blocker may be considered for a patient with multiple ELT episodes or certain ICD detection problems.

Effects of enhanced parasympathetic tone on atrioventricular nodal conduction during atrioventricular nodal reentrant tachycardia

The effects of various physiologic and pharmacologic stimuli on the anterograde slow pathway in patients with atrioventricular nodal reentrant tachycardia are well characterized. We sought to further characterize the nature of anterograde and retrograde conduction during tachycardia and to define the differential input of the parasympathetic nervous system to these pathways. A custom-made neck suction collar was placed to stimulate the carotid body baroreceptors during supraventricular tachycardia. Neck suction at -60 mm Hg was applied and changes in tachycardia cycle length, AH, and ventriculoatrial intervals were measured in 20 patients. These measurements were repeated after intravenous administration of 10 mg of edrophonium to enhance vagal tone. We observed a 15 +/- 6 ms increase in tachycardia cycle length from baseline (p <0.0001) and a 14 +/- 6 ms increase in AH interval (p <0.0001), but no change in the VA interval with neck suction alone. The tachycardia cycle length prolonged 26 +/- 55 ms (p <0.0001) with edrophonium and an additional 12 +/- 43 ms (p <0.001) with neck suction after edrophonium. There was no change in the VA interval before or after edrophonium during neck suction. There were 10 tachycardia terminations in 8 patients during anterograde slow pathway block during neck suction, with tachycardia cycle length prolongation and mean AH prolongation before termination of 45 +/- 37 ms (vs 15 +/- 7 ms increase in AH interval without tachycardia termination, p = 0.10). There were 12 tachycardia terminations in 4 patients with retrograde block during neck suction, only after edrophonium, without any preceding change in tachycardia cycle length during 11 episodes. We conclude that anterograde slow pathway demonstrates gradual conduction slowing with parasympathetic enhancement, whereas retrograde fast pathway responds with abrupt block.

Differentiation of sinus tachycardia from ventricular tachycardia with 1:1 ventriculoatrial conduction in dual chamber implantable cardioverter defibrillators: feasibility of a criterion based on the atrioventricular interval

Tachycardia discrimination in future implantable cardioverter defibrillators (ICDs) is likely to be enhanced by the addition of an atrial sensing/pacing lead. However, differentiation of sinus tachycardia (ST) from ventricular tachycardia (VT) with 1:1 VA conduction will remain problematic. We assessed the use of the AV interval as a potential criterion for correctly differentiating ST from VT. Incremental V pacing at the right ventricular (RV) apex served as a "VT" model in each of 41 patients with 1:1 VA conduction to pacing cycle lengths < or = 450 msec. High right atrial and RV apical electrograms during normal sinus rhythm (NSR) and during incremental V pacing were digitized (simulating ICD sensing). From these signals, AV interval versus pacing cycle length plots were computer generated to identify crossover cycle lengths, each defined as the cycle length at which the AV interval during V pacing equals the AV interval during NSR. At cycle lengths longer than the crossover value, the AV interval during "VT" exceeds the AV interval during NSR. In contrast, the AV interval during ST is physiologically shorter than the AV interval during NSR. Thus, ST can be readily differentiated from "VT" over a range of cycle lengths greater than the crossover value. The overall mean calculated crossover cycle length was 371 +/- 52 msec. In 11 patients paced multiple times, each crossover cycle length was reproducible (mean coefficient of variation was 1.2% +/- 0.9% per patient). AV intervals measured at the RV apex were also analyzed with incremental V pacing during catecholamine stimulation (isoproterenol, n = 5) and during alternate site "VT" (RV outflow tract [n = 8] and left ventricle [n = 2]). In all these cases, the new "VT" plots of AV interval versus pacing cycle length coincided with or fell to the left of those obtained during control RV apical pacing and recording (i.e., these AV interval values crossed the NSR baseline at cycle lengths < or = the crossover cycle length). Thus, the cycle length range for recognizable differentiation of ST from "VT" remained valid. The data suggest that the described AV interval criterion relying on the crossover cycle length: (1) is a promising approach to improve differentiation of ST from relatively slow VTs with 1:1 VA conduction, and (2) can readily be automated in future dual chamber ICDs, given its computational simplicity.

Atrioventricular nodal reentry. Clinical, electrophysiological, and therapeutic considerations

BACKGROUND

Atrioventricular (AV) nodal reentry is a relatively common cause of regular, narrow QRS tachycardia. The underlying basis for this arrhythmia is functional (and anatomic) duality of pathways in the region of the AV node, although the exact boundaries of the reentrant circuit have not been convincingly defined. During the more common type of AV nodal reentry (seen in approximately 90% of cases), a slow conducting pathway is used in the anterograde direction, and a fast pathway is operative in the retrograde direction. In the uncommon form, the direction of impulse propagation within the reentrant circuit is reversed. In this article, the clinical, ECG, and electrophysiological features of AV nodal reentry as well as approaches to therapy are discussed.

METHODS AND RESULTS

Clinical diagnosis may be made from the surface ECG. In the common type of AV nodal reentry, the P wave is obscured by the QRS or may be present in its terminal portion. The P wave in the uncommon form occurs late (i.e., in or after the T wave), producing a pattern of long RP and short PR. Both forms of AV nodal reentry are controllable with various therapeutic modalities. For acute termination, adenosine is probably the ideal agent. Prevention of recurrences can be achieved with several pharmacological agents, including beta-blockers, calcium channel blockers, and class Ia, Ic, and III antiarrhythmic agents. Curative therapy is now available with a variety of nonpharmacological methods. However, the most promising therapy at the present time is catheter modification of the AV node by ablation of either the fast or slow pathway, using radiofrequency energy. Ablation of the fast pathway carries a higher risk of second- or third-degree AV block. Slow pathway ablation, by providing a high rate of success and minimal risk of AV block, seems to be a more acceptable initial approach.

CONCLUSIONS

AV nodal reentry is a common cause of paroxysmal supraventricular tachycardia, and a precise diagnosis can be made with intracardiac electrophysiological evaluation. Although the arrhythmia responds to a variety of antiarrhythmic agents, curative therapy can now be offered with catheter modification of the AV node using radiofrequency energy. At the time of this writing, it seems that catheter modification of the AV node is rapidly becoming the therapy of initial choice in patients with symptomatic AV nodal reentrant tachycardia requiring treatment.

Effects of verapamil on electrophysiological properties in paroxysmal atrial fibrillation

Verapamil is used to control ventricular response during atrial fibrillation (AF). Limited data is available on the effects of verapamil on atrial vulnerability in human AF. The effects of intravenous verapamil (0.15 mg/kg) on electrophysiological properties of the atrium were investigated in 12 patients with documented paroxysmal AF by electrophysiological studies. Sinus cycle length, sinus node recovery time, and the effective refractory period of the right atrium were not significantly affected by verapamil. The intraatrial conduction delay zone was significantly increased (33 +/- 20 msec before verapamil versus 50 +/- 22 msec after verapamil, P < 0.01), and the maximal intraatrial conduction delay was also significantly prolonged by verapamil, both to the His bundle region (30 +/- 12 msec before verapamil versus 42 +/- 15 msec after verapamil, P < 0.01) and to the coronary sinus (40 +/- 15 msec before verapamil versus 53 +/- 17 msec after verapamil, P < 0.01). The fragmented atrial activity zone was significantly increased (15 +/- 14 msec before verapamil versus 25 +/- 22 msec after verapamil, P < 0.02), and the percentile fragmented atrial activity was also significantly increased by verapamil (149 +/- 18 msec before verapamil versus 174 +/- 44 msec after verapamil, P < 0.05). The repetitive atrial firing zone remained unchanged. Sustained AF spontaneously occurred in only one patient after the administration of verapamil. Thus, verapamil may modulate the abnormal atrial electrophysiology in paroxysmal AF, and would favor production of atrial reentry.

Catheter ablation of ventriculoatrial conduction in the treatment of pacemaker-mediated tachycardia

Pacemaker generator reprogramming does not always present an adequate solution to the problem of pacemaker-mediated tachycardia. A case is described where direct current shock catheter ablation of ventriculoatrial conduction prevented pacemaker-mediated tachycardia and allowed optimal dual chamber pacemaker programming.

Atrial electrogram analysis: antegrade versus retrograde

Automatic discrimination between antegrade and retrograde atrial electrograms would prevent endless loop tachycardia and contribute to tachycardia detection algorithms. We tested its feasibility by comparing antegrade and retrograde atrial electrograms in 129 patients at the time of atrial lead implantation. Only unipolar, passive-fixation, endocardial, right atrial appendage leads were included. The mean antegrade amplitude was 4.2 +/- 2.2 mV, and retrograde 2.4 +/- 1.5 mV (P less than 0.001); the mean antegrade slew rate was 2.6 +/- 2.1 mV/ms, and retrograde 1.3 +/- 1.1 mV/ms (P less than 0.001). Morphology was similar in 84 patients (65%). The antegrade amplitude exceeded the retrograde by 1.0 mV in 67%, and by 0.5 mV in 81% of patients. Morphology and slew rate contributed little to the discriminating power of amplitude alone. Thus, amplitude criteria reliably distinguish antegrade from retrograde atrial activity.

Pacemaker-mediated tachycardia: engineering solutions

This discussion summarizes the interaction of refractory periods and upper rate behaviors in modern dual-chamber demand (DDD) devices, the data regarding and nine events initiating VA conduction and engineering solutions proposed and/or implemented to address the problem of pacemaker-mediated tachycardia (PMT). Among the causes of PMT are premature atrial depolarization, loss of atrial capture, a return to the demand mode after asynchronous magnet mode pacing, programming from a mode that does not guarantee AV synchrony to a mode in which atrial tracking can occur, noise, certain situations involving Wenckebach behavior, loss of sensing, and the inability of a rate-smoothing algorithm to allow a rapid change in ventricular rate. Engineering solutions to prevent the occurrence of PMT include a programmable postventricular atrial refractory period (PVARP), differential AV delay, adaptive AV delay, and the ability to discriminate between P waves of atrial origin and those resulting from retrograde conduction from the ventricle. Features such as the ability to lengthen the PVARP for one cycle after exiting the magnet or noise reversion modes or programming to a new mode, lengthen the PVARP for a single cycle following a PVC or revert to DVI pacing for one cycle following a PVC have been developed to recognize initiating events. A third solution, a tachycardia termination algorithm, can recognize and terminate PMT; varying the AV delay to determine whether P waves move in a corresponding manner and using a metabolic sensor to confirm the need for a fast heart rate are other possibilities in the detection of PMT. Diagnostic data features may also be used to evaluate the appropriateness of programmed settings. This discussion concludes that PMT is no longer a significant clinical entity when more advanced DDD pacemakers are utilized.

Atrial sensing to augment ventricular tachycardia detection by the automatic implantable cardioverter defibrillator: a utility study

The triggering of automatic implantable cardioverter defibrillator (AICD) discharges by supraventricular tachycardias, despite the presence of a probability density function algorithm, remains a limitation of an otherwise highly effective device. We systematically investigated the diagnostic utility which theroretically could derive form the addition of atrial sensing capability to the AICD in 25 patients with 30 inducible sustained monomorphic ventricular tachycardias (VTs) at clinically relevant rates (greater than or equal to 150 beats/min). Patients were included only if they were not taking medication capable of depressing ventriculoatrial (VA) conduction for at least 5 half-lives prior to electrophysiological testing. We tested the simple criterion for VT that ventricular cycle length (CL) be shorter than the atrial CL (not met in sinus or most other supraventricular tachycardias). Mean VT CL was 283 +/- 47 ms (range 210 to 370). In 25 (83%) VTs, the VT criterion was consistently satisfied. Of the five cases in which the criterion was not met, 1:1 VA conduction during VT was present in four, three of which initially manifested 2:1 VA conduction lasting from 14 to 28 s and therefore would have transiently fulfilled the VT criterion. The remaining patient who failed to satisfy the VT criterion had ongoing atrial flutter during a relatively slower sustained VT, but this circumstance could be recognized because of the varying AV interval. The absence of 1:1 VA conduction at CLS less than or equal to 400 ms during ventricular pacing accurately predicted the absence of 1:1 VA conduction during VT in 95% of patients.(ABSTRACT TRUNCATED AT 250 WORDS)

Effect of intravenous and oral calcium antagonists (diltiazem and verapamil) on sustenance of atrial fibrillation

Both verapamil and diltiazem are used to control ventricular response during atrial fibrillation (AF). Their effect on the maintenance of AF is not known. The effects of the intravenous and oral administration of verapamil and diltiazem were investigated in 35 patients, 18 with (group I) and 17 without (group II) documented paroxysmal AF. Programmed electrical stimulation, either extra-stimuli or burst atrial pacing, was used to induce AF. In group I, the mean values of the duration of AF before and after the intravenous and oral administration of the calcium antagonists were 31 +/- 12, 112 +/- 49 and 69 +/- 25 minutes, respectively. For group II, the values were 5 +/- 3.4, 39 +/- 13 and 14 +/- 7 minutes, respectively. The differences were statistically highly significant (p less than 0.001), after both oral and intravenous administration compared with the baseline value in both groups. The data suggest that both intravenously and orally administered calcium antagonists enhance sustenance of electrically induced AF, especially in patients with spontaneous arrhythmia. Thus, in patients with paroxysmal AF, verapamil or diltiazem should be administered cautiously, because these drugs may prolong the duration of arrhythmia. Further studies are warranted to investigate the role of calcium antagonists in spontaneously occurring paroxysmal AF.

Effect of concealed anterograde impulse penetration on retrograde atrioventricular nodal conduction in man

The manner in which concealed anterograde impulse penetration may affect retrograde atrioventricular nodal conduction was studied systematically in 12 patients with intact ventriculoatrial (VA) conduction. After the last beat of a basic atrial drive (A1), an extrastimulus (A2) was introduced 20 msec inside the effective refractory period of the atrioventricular node. A ventricular extrastimulus (Vp) was then introduced at a progressively shorter A1Vp coupling interval both in the presence (method I) and absence (method II) of A2. In two patients, Vp was never conducted retrogradely to the atria with method I despite the presence of VA conduction during method II. In the remaining 10 patients, the VpAp interval was longer with method I vs method II; moreover, retrograde block of Vp ultimately occurred at a mean A2Vp coupling interval of 359 +/- 153 msec (range 190 to 540 msec) during method I despite the persistence of VA conduction during method II at comparable A1Vp coupling intervals. Before onset of retrograde block in method I, the VpAp curve took one of the following three forms: (1) crescendo, a progressively increasing VpAp interval; (2) flat, a constant VpAp interval, (four cases); or (3) discontinuous, a marked jump in the VpAp interval before the onset of retrograde block (two cases). Our findings may serve to elucidate some poorly understood electrophysiologic phenomena.

Frequency, diagnosis and clinical characteristics of patients with multiple accessory atrioventricular pathways

Multiple accessory atrioventricular (AV) pathways were documented in 52 of 388 patients (13%) who underwent detailed electrophysiologic evaluation. Multiple AV pathways were identified during intraoperative mapping or electrophysiologic study by different patterns of ventricular preexcitation during atrial fibrillation, flutter or atrial pacing with different delta-wave morphologic and ventricular activation patterns; different sites of atrial activation during right ventricular pacing or orthodromic reciprocating tachycardia; or preexcited reciprocating tachycardia using a second pathway as the retrograde limb of the tachycardia. A logistic model was used to determine which clinical, electrocardiographic and electrophysiologic variables were associated with multiple AV pathways. Right free-wall and posteroseptal accessory AV pathways were more common in patients with multiple AV pathways and were frequently associated. Multivariate logistic regression identified Ebstein's anomaly, and a history of preexcited reciprocating tachycardia as significant variables (p less than 0.0001). Pathway location was not subjected to statistical analysis because of confounding variables.

Discrimination of antegrade and retrograde atrial depolarization by electrogram analysis

The inability of cardiac pacemakers to selectively reject retrograde P waves limits the usefulness of dual-chamber pacemakers (because of the possibility of endless loop tachycardias) and of antitachycardia devices which use a dual-chamber sensing algorithm. In order to determine selective sensing parameters, amplitude, slew rate, and configuration of antegrade and retrograde atrial electrograms were measured in 34 patients undergoing dual-chamber pacemaker implant--31 with unipolar and three with bipolar units. All antegrade and retrograde pairs were measurably different. All 34 cases had measurable antegrade/retrograde amplitude differences; 30 of the unipolar cases (96.8%) and all bipolar cases displayed antegrade/retrograde amplitude differences of at least 0.25 mV. Thirty of the unipolar cases (96.8%) and two bipolar cases had measurable slew rate differences. Configuration differed in 14 of 31 (45.2%) of unipolar and in two bipolar cases. A combined criterion with 0.25 mV sensitivity steps (available in at least two presently available pacemakers) and 0.5 V/sec slew rate gradations (through the use of externally programmable filters) would allow the discrimination of retrograde from antegrade depolarizations in all 34 cases. With the use of amplitude and slew rate differences, it is therefore possible to reject retrograde P waves while sensing antegrade P waves with current technology.

Noninvasive assessment of ventriculo-atrial conduction and early experience with the tachycardia termination algorithm in pacemaker-mediated tachycardia

Since the advent of physiologic dual chamber pacing systems, pacemaker-mediated tachycardia (PMT) has occurred and the need for invasive measurement of ventriculo-atrial conduction (VAC) has arisen. The variability in VAC and the potential for PMT often make it necessary to assess for the presence or absence of VAC at different points in time. We noninvasively evaluated 20 pacemaker patients for the presence or absence of VAC. We compared ventriculo-atrial conduction time (VACT) obtained with the atrial sense event maker with that obtained from Holter monitoring and invasive methods. The incidence of spontaneous (S) and induced (I) PMT and the efficacy of the tachycardia termination algorithm (TTA) was assessed. Fourteen of 20 had VAC with invasive or noninvasive methods. Twelve of 19 had PMT (63%); three were sustained (greater than 15 beats). We conclude that VACT assessed with the atrial sense event marker (ASEM) yielded a high correlation when compared to the Holter monitor data obtained utilizing our methodology. PMT is commonly a nonsustained (less than 15 beats) event, and the TTA is effective in sustained PMT. Myopotential sensing, atrial premature contractions and loss of atrial capture are common mechanisms in the initiation of PMT.

Pacemaker-mediated tachycardias: an unresolved problem

The advent of dual chamber pacing systems that restore atrioventricular synchrony and allow rate variability in response to physiologic stress has provided a major advance in pacing therapy. Undesirable pacemaker-mediated tachycardias may arise when the atrial sensing amplifier of a VDD or DDD device detects a retrogradely conducted P-wave, ectopic atrial tachycardia, myopectoral contractions, or environmental electromagnetic interference. The rate of the resultant tachycardia is determined by the programmed upper tracking rate of the pacemaker. Although seldom life-threatening, troublesome myocardial ischemia may ensue in patients with coronary artery disease. In most instances, the incidence and rate of pacemaker-mediated tachycardias may be minimized by judicious programming.

Effect of verapamil on retrograde conduction in atrioventricular nodal reentrant tachycardia

Using His bundle electrograms, incremental ventricular pacing and the ventricular extrastimulus (V2) technique, the effects of intravenous verapamil, 0.2 mg/kg, on retrograde atrioventricular (AV) nodal conduction during ventricular pacing, premature ventricular stimulation (H2A2 interval) and paroxysmal supraventricular tachycardia (SVT) (H-Ae interval) were evaluated in 11 patients with AV nodal reentrant tachycardia. During the control study, SVT could be induced in all 11 patients. After verapamil administration, SVT or atrial echo beats could be induced in 5 patients. Verapamil produced ventriculoatrial (VA) block at a longer cycle length than that during the control study in 10 of 11 patients (295 +/- 27 vs 352 +/- 40 ms, p less than 0.01), but prolonged H2A2 interval in only 5 of 11 patients (37 +/- 6 vs 60 +/- 31 ms, p less than 0.05). In all 5 patients with persistence of inducible SVT or atrial echo beats after verapamil treatment, the H-Ae interval remained unchanged even though in 4 of these 5 patients VA conduction time or H2A2 interval was prolonged. Correlation between the paced cycle length which induced VA block, the shortest V1H2 interval achieved during premature ventricular stimulation and the cycle length of SVT revealed that in all instances in which verapamil induced VA block at a longer cycle length than in controls but did not prolong H2A2 or H-Ae interval, the shortest V1H2 interval and the cycle length of SVT (H-H interval) were significantly longer than the ventricular paced cycle length which produced VA block.(ABSTRACT TRUNCATED AT 250 WORDS)

Preexcited reciprocating tachycardia in patients with Wolff-Parkinson-White syndrome: incidence and mechanisms

During the electrophysiologic study of 435 patients referred for evaluation of Wolff-Parkinson-White syndrome, 42 (10%) had preexcited reciprocating tachycardia (defined as a macro-reentrant tachycardia that used an accessory atrioventricular [AV] pathway for antegrade conduction). The ages of the patients ranged from 9 to 67 years (27 +/- 14). Thirty-three were male patients, nine female, and eight had Ebstein's anomaly. Preexcited reciprocating tachycardia cycle length was 220 to 430 msec (294 +/- 42). Significant hemodynamic compromise in the laboratory directly related to preexcitated reciprocating tachycardia occurred in only one patient. However, in 10 patients a transformation to atrial fibrillation was seen after a spontaneously occurring premature atrial contraction. Only 17 of the 42 patients with preexcited reciprocating tachycardia during electrophysiologic study had the same tachycardia documented clinically. These 17 patients were more often younger with multiple accessory pathways and with no history of orthodromic reciprocating tachycardia when compared with 25 patients in whom preexcited reciprocating tachycardia could be induced only in the laboratory. Preexcited reciprocating tachycardia was induced in the laboratory in 22 of 374 (6%) patients with single accessory pathways and in 20 of 61 (33%) of those with multiple accessory pathways. In the 20 patients with multiple accessory pathways, the spectrum of reentrant circuits included fusion over two or more accessory pathways or fusion over both an accessory pathway and the AV node. In the 22 patients with a single accessory pathway and true antidromic reciprocating tachycardia, all but two episodes were at least 4 cm from the AV node. No patient with true antidromic reciprocating tachycardia had a posterior septal accessory AV pathway. Only in patients with multiple accessory pathways was the posterior septal accessory AV pathway used as the antegrade limb.